文献速递临床试验与 GCP流行病学与生物统计

比较耐多药结核病患者自我给药治疗与直接观察治疗的依从性:非劣效性随机对照试验

Comparing adherence to MDR-TB treatment among patients on self-administered therapy and those on directly observed therapy: non-inferiority randomized controlled trial.
PubMed 文献 · Trials · 2023-05-12

该研究为开放标签非劣效性随机对照试验,计划在乌干达三所地区医院纳入164例年龄≥8岁的新诊断耐多药结核病患者,随机分为自我给药治疗组(用药物事件监测系统MEMS技术监测依从性)和卫生机构直接观察治疗(DOT)对照组,每月随访,主要结局为两组依从率比较。

要点

  • 计划纳入164例新诊断耐多药结核病患者,年龄≥8岁,来自乌干达三所地区医院。
  • 干预组采用自我给药治疗并以MEMS技术监测依从性,对照组为卫生机构直接观察治疗。
  • 主要结局为两组依从率的比较,每月随访。

核心结论

  • 评估耐多药结核病患者自我给药治疗对于制定成本有效的管理策略很重要,全口服方案的批准为MEMS技术等创新提供了支持低资源环境下可持续治疗依从性支持的机会。

研究设计与样本

  • 开放标签非劣效性随机对照试验,计划纳入164例年龄≥8岁的新诊断耐多药结核病患者,来自乌干达三所位于农村和城市的地区医院。
  • 排除影响手部灵巧性和操作MEMS药物设备能力的患者。
  • 患者随机分为自我给药治疗组(干预组,用MEMS技术监测依从性)或卫生机构直接观察治疗组(对照组),每月随访。

主要发现

  • 干预组依从性通过MEMS软件记录的药瓶打开取药天数测量,对照组通过结核病治疗卡记录的治疗投诉天数测量。
  • 主要结局为两组依从率的比较。

关键数值与推荐

  • 依从性测量:干预组为MEMS软件记录的药瓶打开取药天数,对照组为结核病治疗卡记录的治疗投诉天数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验注册为回顾性注册,于2022年5月13日注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adherence is key to the treatment success of multi-drug resistant tuberculosis (MDR-TB) and prevention of community transmission. Directly observed therapy (DOT) is the recommended approach for the management of patients with MDR-TB. Uganda implements a health facility-based DOT approach where all patients diagnosed with MDR-TB report to the nearest private or public health facility for daily observation of ingesting their medicines by a health care provider. Directly observed therapy is very costly for both the patient and health care system. It follows the assumption that MDR TB patients have a history of poor adherence to TB treatment. But only 21% of MDR-TB patients notified globally and 1.4-12% notified in Uganda had been previously treated for TB. The shift to all oral treatment regimen for MDR-TB provides an opportunity for the exploration of self-administered therapy for this group of patients even with use of remotely operated adherence technology. We are conducting a non-inferiority open-label randomized controlled trial to compare adherence to MDR-TB treatment among patients on self-administered therapy (measured by Medication Events Monitoring System (MEMS) technology) with a control group on DOT. METHODS: We plan to enrol 164 newly diagnosed MDR-TB patients aged ≥ 8 years from three regional hospitals based in rural and urban Uganda. Patients with conditions that affect their dexterity and ability to operate the MEMS-operated medicine equipment will not be eligible to participate in the trial. Patients are randomized to either of the two study arms: self-administered therapy with adherence being monitored using MEMS technology (intervention arm) or health facility-based DOT (control arm) and will be followed up monthly. Adherence is measured by the number of days the medicine bottle is open to access medication as recorded by the MEMS software in the intervention arm and treatment complaint days as recorded in the TB treatment card in the control arm. The primary outcome is the comparison of adherence rates between the two study arms. DISCUSSION: The evaluation of self-administered therapy for patients with MDR-TB is important to inform cost-effective management strategies for these patients. The approval of all oral regimens for the treatment of MDR-TB provides an opportunity for innovations such as MEMS technology to support sustainable options for MDR-TB treatment adherence support in low-resource settings. TRIAL REGISTRATION: Pan African Clinical Trials Registry, Cochrane #PACTR202205876377808. Retrospectively registered on 13 May 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wekesa C, Sekaggya-Wiltshire C, Muyanja SZ, et al. Comparing adherence to MDR-TB treatment among patients on self-administered therapy and those on directly observed therapy: non-inferiority randomized controlled trial. Trials. 2023. PMID: 37173761. doi:10.1186/s13063-023-07314-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。